Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Leukemia 42Lymphoma 33Melanoma 32Breast Neoplasms 31Leukemia, Myeloid, Acute 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia, Lymphocytic, Chronic, B-Cell 23Lymphoma, Non-Hodgkin 22Multiple Myeloma 21Lymphoma, Follicular 21Myelodysplastic Syndromes 19Prostatic Neoplasms 18Neuroblastoma 18Lymphoma, Mantle-Cell 17Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 16Hodgkin Disease 15Neoplasms, Plasma Cell 14Lymphoma, Large-Cell, Immunoblastic 14Ovarian Neoplasms 13Lung Neoplasms 13Congenital Abnormalities 13Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Accelerated Phase 12Carcinoma, Non-Small-Cell Lung 12Burkitt Lymphoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11Glioblastoma 11Carcinoma, Ovarian Epithelial 11Colorectal Neoplasms 10

Interventions

Vincristine 3Topotecan 3Stem Cell Transplantation 3Radiation 3Platinum 3Melphalan 3Doxorubicin 3Cyclophosphamide 3Congresses as Topic 3Cisplatin 31,2-diaminocyclohexaneplatinum II citrate 3sargramostim 2dinutuximab 2Isotretinoin 2Etoposide 2Colony-Stimulating Factors 2Busulfan 2temsirolimus 1etoposide phosphate 1Thiotepa 1Temozolomide 1Sirolimus 1Razoxane 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Peripheral Blood Stem Cell Transplantation 1Mesna 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Ganglioneuroblastoma × sargramostim × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT01767194 2022-10-24

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
73 enrolled 12 charts
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡